Results 1 to 10 of about 16,195 (165)
Direct-acting antivirals and visceral leishmaniasis: a case report [PDF]
BMC Infectious Diseases, 2019 Background Visceral leishmaniasis is a vector-borne parasitic disease caused by protozoa belonging to the genus Leishmania. The clinical presentation of visceral leishmaniasis strictly depends on the host immunocompetency, whereas depressive conditions ...
Claudia Colomba +7 more
doaj +4 more sources
Current and Future Direct-Acting Antivirals Against COVID-19 [PDF]
Frontiers in Microbiology, 2020 The coronavirus disease of 2019 (COVID-19) has caused an unprecedented global crisis. The etiological agent is a new virus called the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). As of October, 2020 there have been 45.4 million confirmed
Shiu-Wan Chan
doaj +3 more sources
Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis [PDF]
Scientifica, 2012 The development and evaluation of antiviral agents through carefully designed clinical trials over the last 25 years have heralded a new dawn in the treatment of patients chronically infected with the hepatitis B and C viruses, but not so for the D virus
Peter Karayiannis
doaj +3 more sources
Virus infection and direct-acting antivirals in pregnancy
Clinical and Experimental Obstetrics & Gynecology, 2022 Objective: Antiviral therapy during pregnancy has always presented difficulties in clinical practice. This review covers the safety and efficacy of the direct use of antivirals during pregnancy.
Xuan Huang, Jing Tang
doaj +2 more sources
Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
Viruses, 2015 There has been a remarkable transformation in the treatment of chronic hepatitis C in recent years with the development of direct acting antiviral agents targeting virus encoded proteins important for viral replication including NS3/4A, NS5A and NS5B ...
Asma Ahmed, Daniel J. Felmlee
doaj +3 more sources
Management of Direct‐Acting Antiviral Failures [PDF]
Clinical Liver Disease, 2020 Answer questions and earn CME.
Maryam, Alimirah +2 more
openaire +2 more sources
Frequency of Hepatocellular Carcinoma in Cirrhotic Patients after Chronic Hepatitis C Infection Treatment with Direct-Acting Antivirals [PDF]
Afro-Egyptian Journal of Infectious and Endemic Diseases, 2022 Background and study aim: Hepatocellular carcinoma (HCC) is the 4th most common cancer in Egypt and is the 2nd leading cause of cancer-related death in both men and women. The aim of this study is to determine the frequency of HCC in cirrhotic patients
Ahmed Sharaf +3 more
doaj +1 more source
Treatment of Chronic HCV Infection with Direct Acting Antivirals
Central Asian Journal of Medical Sciences, 2021 Objectives: This study was conducted to discover the treatment outcome and side effects of chronic hepatitis C virus patients treated with Direct-Acting Antivirals (DAAs).
Bekhbold Dashtseren +12 more
doaj +1 more source
The Egyptian Journal of Internal Medicine, 2022 Background Direct-acting antivirals (DAAs) have revolutionized the therapy of HCV infection with higher sustained virological response (SVR) rates. Fibrosis regression after achieving SVR to DAA remains to be evaluated in chronic hepatitis C patients ...
Ramy H. Agwa +5 more
doaj +1 more source
Planning a clinical trial programme for direct-acting antivirals for chronic viral hepatitis C
Регуляторные исследования и экспертиза лекарственных средств, 2023 Scientific relevance. Direct-acting antivirals have significantly improved the effectiveness of treatment for hepatitis C. However, Russia and the Eurasian Economic Union lack recommendations for the clinical development of medicinal products from this ...
A. I. Gubenko +3 more
doaj +1 more source